Erectile dysfunction with secukinumab

Psoriasis is a chronic immune-mediated inflammatory skin disease that requires long-term management using systemic agents in moderate-to-severe cases.Secukinumab, a monoclonal antibody targeting interleukin-17A, is commonly used for treatment.We report a 43-year-old Korean man with psoriasis who developed severe erectile dysfunction after one year of secukinumab.He had no history of psychological disorders, metabolic disease, trauma, or substance use.After switching to ixekizumab, another interleukin-17A inhibitor, his erectile function markedly improved.The close temporal relationship between symptom onset and drug exposure, along with symptom improvement after the switch, supports a possible causal relationship.This is the second reported case of erectile dysfunction associated with secukinumab and the first in Korea.Although uncommon, erectile dysfunction may occur during interleukin-17A inhibitor therapy and should be considered in patients reporting sexual dysfunction.